BioForce Nanosciences Holdings Inc logo

BFNH - BioForce Nanosciences Holdings Inc News Story

$0.7 0.0  0.0%

Last Trade - 20/04/21

Consumer Cyclicals
Micro Cap
Market Cap £14.7m
Enterprise Value £14.7m
Revenue £n/a
Position in Universe 6142nd / 6852

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) Becomes Fully Reporting Per US SEC 1934 Act Rules

Thu 2nd August, 2018 2:46pm
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) Becomes Fully Reporting Per US SEC 1934 Act Rules

VIRGINIA BEACH, Va., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BIOFORCE NANOSCIENCES HOLDINGS, INC. (OTCMARKETS:BFNH) announces that the US SEC regulators approved the Company’s FORM 10 registration under the 1934 Exchange Act (“Act”).

As of August 1, 2018, the Company is fully transparent and filing reports within the rules/regulations required of the 1934 Act.

The US SEC approval of the Company under the “Act” shows, under federal rules/regulations, that BFNH meets the necessary statues per financial auditing and disclosures standards.  Being a “34 Act” entity allows the Company certain benefits which were not attainable otherwise.  As such, brokerage houses, national stock exchanges, and other financial institutions require publicly traded entities to be a “34 Act reporting” issuer for trading and listing requirements. Shareholders who own 144 restricted shares can now register their holdings as “free-trade” after a 6-month holding time versus that of 1-year for non-reporting status.

The Company’s shareholders can be assured that the arduous process and cost of becoming fully-reporting was an important fiduciary responsibility of BFNH’s board and management team.

Management believes in a productive future ahead, and being a fully-reporting entity now allows BFNH to negotiate future acquisitions with reasonable terms. BFNH’s management team continues to aggressively look at a number of unique businesses operations with acquisition intentions. 

For further information about this release, contact YES INTERNATIONAL, Investor Relations, 757-306-6090, and

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

 CONTACT:Bioforce NanoSciences Holdings, Inc.
 Rich Kaiser, 757-306-6090

© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.